94 related articles for article (PubMed ID: 24067109)
1. MicroRNA let-7f is down-regulated in patients with refractory acute myeloid leukemia and is involved in chemotherapy resistance of adriamycin-resistant leukemic cells.
Dai CW; Bai QW; Zhang GS; Cao YX; Shen JK; Pei MF; Yin CC
Leuk Lymphoma; 2014 Jul; 55(7):1645-8. PubMed ID: 24067109
[No Abstract] [Full Text] [Related]
2. Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line.
Cao YX; Wen F; Luo ZY; Long XX; Luo C; Liao P; Li JJ
J Cell Biochem; 2020 Oct; 121(10):4022-4033. PubMed ID: 31793054
[TBL] [Abstract][Full Text] [Related]
3. Letting microRNAs overcome resistance to chemotherapy in acute myeloid leukemia.
Sakamoto KM
Leuk Lymphoma; 2014 Jul; 55(7):1449-50. PubMed ID: 24206095
[No Abstract] [Full Text] [Related]
4. MicroRNA-103 confers the resistance to long-treatment of adriamycin to human leukemia cells by regulation of COP1.
Wan L; Tian Y; Zhang R; Peng Z; Sun J; Zhang W
J Cell Biochem; 2018 May; 119(5):3843-3852. PubMed ID: 29058777
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
Feng R; Dong L
Int J Clin Exp Pathol; 2015; 8(6):6107-16. PubMed ID: 26261488
[TBL] [Abstract][Full Text] [Related]
6. Downregulated miR‑130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin.
Liu H; Liu M; Zhang J; Liang Y
Mol Med Rep; 2020 Oct; 22(4):2810-2816. PubMed ID: 32945422
[TBL] [Abstract][Full Text] [Related]
7. Endogenous tumor necrosis factor and doxorubicin sensitivity in leukemic patients.
Watanabe N
Leuk Lymphoma; 1998 Aug; 30(5-6):477-82. PubMed ID: 9711910
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
[TBL] [Abstract][Full Text] [Related]
9. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
Lu F; Zhang J; Ji M; Li P; Du Y; Wang H; Zang S; Ma D; Sun X; Ji C
Int J Oncol; 2014 Jul; 45(1):383-92. PubMed ID: 24756163
[TBL] [Abstract][Full Text] [Related]
10. Expression of three different ATP-binding cassette transporters and correlation to chemoresistance in acute myeloid leukemia.
Palaiologou D; Panayiotidis P; Papanikolaou G; Georgiou G; Boutsikas G; Hatzinicolaou SL; Pangalis GA; Sakellaropoulos N; Vassilakopoulos TP; Angelopoulou MK
Int J Lab Hematol; 2015 Feb; 37(1):e7-e10. PubMed ID: 24809224
[No Abstract] [Full Text] [Related]
11. Identification of chemoresistance-related cell-surface glycoproteins in leukemia cells and functional validation of candidate glycoproteins.
Sun Z; Dong J; Zhang S; Hu Z; Cheng K; Li K; Xu B; Ye M; Nie Y; Fan D; Zou H
J Proteome Res; 2014 Mar; 13(3):1593-601. PubMed ID: 24467213
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of mitochondrial ATPsyn-β in acute myeloid leukemia cells and with increased drug resistance.
Xiao X; Yang J; Li R; Liu S; Xu Y; Zheng W; Yi Y; Luo Y; Gong F; Peng H; Pei M; Deng M; Zhang G
PLoS One; 2013; 8(12):e83610. PubMed ID: 24391795
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
14. Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis.
Song JH; Choi CH; Yeom HJ; Hwang SY; Kim TS
Life Sci; 2006 Jun; 79(2):193-202. PubMed ID: 16458935
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression.
Kweon SH; Song JH; Kim TS
Biochem Biophys Res Commun; 2010 Apr; 395(1):104-10. PubMed ID: 20350534
[TBL] [Abstract][Full Text] [Related]
16. [Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines].
Cao YX; Dai CW; Zhang GS
Zhonghua Xue Ye Xue Za Zhi; 2010 Jun; 31(6):361-5. PubMed ID: 21122348
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
[TBL] [Abstract][Full Text] [Related]
18. MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer.
Zhao D; Zhang Y; Song L
Pathol Oncol Res; 2018 Jul; 24(3):483-488. PubMed ID: 28667493
[TBL] [Abstract][Full Text] [Related]
19. MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism.
Pan C; Wang X; Shi K; Zheng Y; Li J; Chen Y; Jin L; Pan Z
PLoS One; 2016; 11(5):e0152090. PubMed ID: 27138141
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells.
Tian C; Zheng G; Zhuang H; Li X; Hu D; Zhu L; Wang T; You MJ; Zhang Y
J Cell Physiol; 2017 Jun; 232(6):1387-1395. PubMed ID: 27696394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]